查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1566969

布魯氏菌病疫苗市場：按類型、按疫苗、動物類型、按最終用戶：2024-2033 年全球機會分析和產業預測

Brucellosis Vaccines Market By Type , By Vaccine By Animal Type By End User : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 280 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2023年布魯氏菌病疫苗市值為2億美元，預計2024年至2033年複合年成長率為6.4%，到2033年將達4億美元。

布魯氏菌病疫苗是預防和控制布魯氏菌病（一種由布氏桿菌屬引起的通用感染疾病）的重要工具。該疾病感染多種牲畜，包括牛、綿羊和山羊，導致流產和生育力下降等繁殖障礙，對農業部門造成重大經濟損失。在人類中，布魯氏菌病可引起從輕微的類流感症狀到嚴重的慢性症狀的各種症狀。牲畜疫苗接種是減少布氏桿菌屬從動物傳播給人類的關鍵，在公共衛生和食品安全中發揮重要作用。

全球布魯氏菌病疫苗市場的成長是由於牲畜布魯氏菌病發病率上升，特別是在農業活動頻繁的地區，以及農民和牲畜所有者對預防布魯氏菌病疫苗接種重要性的認知不斷提高而帶來的。根據世界領先的醫學研究中心之一美國國立衛生研究院發表的一項研究，布氏桿菌症是最常見的通用感染疾病之一，每年影響 50 萬人。隨著全球對肉類和乳製品的需求不斷增加，保護牲畜免受布氏桿菌症等疾病侵害的需求不斷增加，進一步推動了布魯氏菌病疫苗市場的發展。此外，由於布氏桿菌症是一種人畜共通感染疾病，可以傳播給人類，因此人們專注於控制牲畜疾病以保護人類健康，這推動了對疫苗的需求。此外，不斷增加的區域和國家疫苗宣傳活動，特別是在布魯氏菌病是一個重要公共衛生問題的國家，正在為市場成長做出重大貢獻。此外，對「統一健康」概念的強調，即關注人類、動物和環境健康的相互聯繫，正在影響布魯氏菌病疫苗市場。這種整體方法正在導致人們綜合努力控制動物和人類的布魯氏菌病，特別是在布魯氏菌病流行的地區。然而，開拓新的有效布魯氏菌病疫苗的高成本阻礙了全球市場的成長。此外，由於基因突變而出現的布氏桿菌屬菌疫苗抗性菌株降低了現有疫苗的有效性，並顯著抑制了市場成長。相反，疫苗技術的進步，例如開發更有效、更安全的疫苗，透過提高疾病控制的有效性而促進市場成長。此外，生物技術的進步正在推動疫苗生產的創新，包括重組 DNA 技術和其他分子技術的使用。這些創新正在提高布魯氏菌病疫苗的功效和安全性，使其更容易取得和擴展。

全球布魯氏菌病疫苗產業分為類型、疫苗、動物類型、最終用戶和地區。按類型分類，市場分為 RBS1、S19 和 B19。疫苗分為DNA疫苗、次單位疫苗、載體疫苗、重組疫苗。依動物種類可分為牛、綿羊、山羊。按最終用戶分類，該細分市場分為獸醫醫院和診所、動物護理中心等。從區域來看，分析涵蓋北美、歐洲、亞太地區和拉丁美洲/中東/非洲。

主要發現

按類型分類，RBS1 細分市場在 2023 年佔據主導市場佔有率。

從疫苗來看，DNA疫苗領域是2023年市場的主要股東。

按動物類型分類，牛將成為 2023 年的主導部分。

按最終用戶分類，獸醫院/診所在 2023 年佔據了最大佔有率。

按地區分類，北美在 2023 年佔據主導地位，而亞太地區預計在預測期內複合年成長率最高。

可以自訂此報告（需要額外的費用和時間表）

  • 按產品/細分市場細分
  • 新產品開發/主要企業產品矩陣
  • 監管指引
  • 根據客戶興趣新增其他公司簡介
  • 按國家或地區進行的附加分析 – 市場規模和預測
  • 擴大公司簡介列表
  • 歷史市場資料
  • 主要參與企業的詳細資料（Excel格式，包括位置、聯絡資訊、供應商/供應商網路等）

目錄

第1章簡介

第 2 章執行摘要

第3章 市場狀況

  • 市場定義和範圍
  • 主要發現
    • 關鍵投資機會
    • 關鍵成功策略
  • 波特五力分析
  • 市場動態
    • 促進因素
    • 抑制因素
    • 機會

第4章布魯氏菌病疫苗市場：依類型

  • 市場概況
  • RBS1
  • S19
  • B19

第5章布魯氏菌病疫苗市場：依疫苗分類

  • 市場概況
  • DNA疫苗
  • 次單位疫苗
  • 載體疫苗
  • 重組疫苗

第6章布魯氏菌病疫苗市場：依動物類型

  • 市場概況
  • 牛
  • 羊
  • 山羊

第7章布魯氏菌病疫苗市場：依最終用戶分類

  • 市場概況
  • 獸醫醫院和診所
  • 動物照護中心
  • 其他

第8章布魯氏菌病疫苗市場：按地區

  • 市場概況
  • 北美洲
    • 主要市場趨勢和機遇
    • 美國布魯氏菌病疫苗市場
    • 加拿大布魯氏菌病疫苗市場
    • 墨西哥布魯氏菌病疫苗市場
  • 歐洲
    • 主要市場趨勢和機遇
    • 德國布魯氏菌病疫苗市場
    • 法國布魯氏菌病疫苗市場
    • 英國布魯氏菌病疫苗市場
    • 義大利布魯氏菌病疫苗市場
    • 西班牙布魯氏菌病疫苗市場
    • 其他歐洲布魯氏菌病疫苗市場
  • 亞太地區
    • 主要市場趨勢和機遇
    • 日本布魯氏菌病疫苗市場
    • 中國布魯氏菌病疫苗市場
    • 澳洲布魯氏菌病疫苗市場
    • 印度布魯氏菌病疫苗市場
    • 韓國布魯氏菌病疫苗市場
    • 其他亞太布魯氏菌病疫苗市場
  • 拉丁美洲/中東/非洲
    • 主要市場趨勢和機遇
    • 巴西布魯氏菌病疫苗市場
    • 沙烏地阿拉伯布魯氏菌病疫苗市場
    • 南非布魯氏菌病疫苗市場
    • 其他拉丁美洲/中東/非洲布魯氏菌病疫苗市場

第9章 競爭格局

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 競爭對手儀表板
  • 競爭熱圖
  • 主要企業定位（2023年）

第10章 公司簡介

  • Ceva Poultry
  • Colorado Serum Company
  • Creative Biolabs
  • CZ Vaccines
  • Fivet Animal Health
  • Hester Biosciences Limited
  • Indian Immunologicals Ltd
  • Jordan Bio-industries Center
  • Laboratories Tornel
  • Merck And Co., Inc.
簡介目錄
Product Code: A324385

The brucellosis vaccines market was valued at $0.2 billion in 2023, and is projected to reach $0.4 billion by 2033, growing at a CAGR of 6.4% from 2024 to 2033.

Brucellosis vaccine is a critical tool used in the prevention and control of brucellosis, a zoonotic bacterial infection caused by Brucella species. This disease affects various livestock, including cattle, sheep, and goats, leading to reproductive failures such as abortions, reduced fertility, and significant economic losses in the agricultural sector. In humans, brucellosis can cause a range of symptoms, from mild flu-like illness to severe, chronic conditions. Vaccination of livestock is a cornerstone in reducing the transmission of Brucella from animals to humans, thus playing a vital role in public health and food safety.

The growth of the global brucellosis vaccines market is driven by rise in incidence of brucellosis in livestock, particularly in regions with significant agricultural activity, and increase in awareness among farmers and livestock owners about the importance of vaccination in preventing brucellosis. According to a study published by the National Institutes of Health-one of the world's foremost medical research centers-brucellosis is one the most common zoonotic diseases affecting 500,000 cases annually. As the global demand for meat and dairy products grows, there is a corresponding increase in the need to protect livestock from diseases like brucellosis, further driving the brucellosis vaccine market. Moreover, with brucellosis being a zoonotic disease that can be transmitted to humans, there is an increasing focus on controlling the disease in animals to protect human health, which, in turn, fosters the demand for vaccines. Furthermore, increase in trend of regional and national vaccination campaigns, particularly in countries where brucellosis is a significant public health issue, is notably contributing toward the market growth. In addition, emphasis on the One Health concept, which focuses on the interconnectedness of human, animal, and environmental health, is influencing the brucellosis vaccination market. This holistic approach is leading to integrated efforts to control brucellosis in both animals and humans, particularly in regions where the disease is endemic. However, high cost associated with development of new and effective brucellosis vaccines is hampering the growth of the global market. In addition, the emergence of vaccine-resistant strains of Brucella due to genetic variability has reduced the effectiveness of existing vaccines, which significantly restrained the market growth. On the contrary, advancements in vaccine technology, such as the development of more effective and safer vaccines, are contributing to market growth by improving the efficacy of disease control measures. Moreover, advances in biotechnology are driving innovations in vaccine production, including the use of recombinant DNA technology and other molecular techniques. These innovations are enhancing the efficacy and safety of brucellosis vaccines, making them more accessible and scalable.

The global brucellosis vaccines industry is segmented into type, vaccine, animal type, end user, and region. By type, the market is divided into RBS1, S19, and B19. As per vaccine, it is segregated into DNA vaccine, subunit vaccine, vector vaccine, and recombinant vaccine. By animal type, it is fragmented into cattle, sheep, and goat. Depending on end user, it is fragmented into veterinary hospitals & clinics, animal care centers, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By type, the RBS1 segment dominated the market share in 2023.

As per vaccine, the DNA vaccine segment was the major shareholder in the market in 2023.

On the basis of animal type, cattle emerged as the leading segment in 2023.

Depending on end user, the veterinary hospitals & clinics segment garnered the largest share in 2023.

Region wise, North America held the dominant position in 2023; however, Asia-Pacific is expected to register highest CAGR during the forecast period.

Competition Analysis

Competitive analysis and profiles of the major players in the global brucellosis vaccines market include Ceva Poultry, Colorado Serum Company, Creative Biolabs, CZ Vaccines, Fivet Animal Health, Hester Biosciences Limited, Indian Immunologicals Ltd, Jordan Bio-industries Center, Laboratories Tornel, and Merck & Co., Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and gain a strong foothold in the global market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Market share analysis of players by products/segments
  • New Product Development/ Product Matrix of Key Players
  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Type

  • RBS1
  • S19
  • B19

By Vaccine

  • DNA Vaccine
  • Subunit Vaccine
  • Vector Vaccine
  • Recombinant Vaccine

By Animal Type

  • Cattle
  • Sheep
  • Goat

By End User

  • Veterinary Hospitals and Clinics
  • Animal Care Centers
  • Other

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Ceva Poultry
    • Colorado Serum Company
    • Creative Biolabs
    • CZ Vaccines
    • Fivet Animal Health
    • Hester Biosciences Limited
    • Indian Immunologicals Ltd
    • Jordan Bio-industries Center
    • Laboratories Tornel
    • Merck & Co., Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: BRUCELLOSIS VACCINES MARKET, BY TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Type
  • 4.2. RBS1
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. S19
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. B19
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country

CHAPTER 5: BRUCELLOSIS VACCINES MARKET, BY VACCINE

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Vaccine
  • 5.2. DNA Vaccine
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Subunit Vaccine
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country
  • 5.4. Vector Vaccine
    • 5.4.1. Key Market Trends, Growth Factors and Opportunities
    • 5.4.2. Market Size and Forecast, By Region
    • 5.4.3. Market Share Analysis, By Country
  • 5.5. Recombinant Vaccine
    • 5.5.1. Key Market Trends, Growth Factors and Opportunities
    • 5.5.2. Market Size and Forecast, By Region
    • 5.5.3. Market Share Analysis, By Country

CHAPTER 6: BRUCELLOSIS VACCINES MARKET, BY ANIMAL TYPE

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Animal Type
  • 6.2. Cattle
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Sheep
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country
  • 6.4. Goat
    • 6.4.1. Key Market Trends, Growth Factors and Opportunities
    • 6.4.2. Market Size and Forecast, By Region
    • 6.4.3. Market Share Analysis, By Country

CHAPTER 7: BRUCELLOSIS VACCINES MARKET, BY END USER

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By End User
  • 7.2. Veterinary Hospitals And Clinics
    • 7.2.1. Key Market Trends, Growth Factors and Opportunities
    • 7.2.2. Market Size and Forecast, By Region
    • 7.2.3. Market Share Analysis, By Country
  • 7.3. Animal Care Centers
    • 7.3.1. Key Market Trends, Growth Factors and Opportunities
    • 7.3.2. Market Size and Forecast, By Region
    • 7.3.3. Market Share Analysis, By Country
  • 7.4. Other
    • 7.4.1. Key Market Trends, Growth Factors and Opportunities
    • 7.4.2. Market Size and Forecast, By Region
    • 7.4.3. Market Share Analysis, By Country

CHAPTER 8: BRUCELLOSIS VACCINES MARKET, BY REGION

  • 8.1. Market Overview
    • 8.1.1 Market Size and Forecast, By Region
  • 8.2. North America
    • 8.2.1. Key Market Trends and Opportunities
    • 8.2.2. Market Size and Forecast, By Type
    • 8.2.3. Market Size and Forecast, By Vaccine
    • 8.2.4. Market Size and Forecast, By Animal Type
    • 8.2.5. Market Size and Forecast, By End User
    • 8.2.6. Market Size and Forecast, By Country
    • 8.2.7. U.S. Brucellosis Vaccines Market
      • 8.2.7.1. Market Size and Forecast, By Type
      • 8.2.7.2. Market Size and Forecast, By Vaccine
      • 8.2.7.3. Market Size and Forecast, By Animal Type
      • 8.2.7.4. Market Size and Forecast, By End User
    • 8.2.8. Canada Brucellosis Vaccines Market
      • 8.2.8.1. Market Size and Forecast, By Type
      • 8.2.8.2. Market Size and Forecast, By Vaccine
      • 8.2.8.3. Market Size and Forecast, By Animal Type
      • 8.2.8.4. Market Size and Forecast, By End User
    • 8.2.9. Mexico Brucellosis Vaccines Market
      • 8.2.9.1. Market Size and Forecast, By Type
      • 8.2.9.2. Market Size and Forecast, By Vaccine
      • 8.2.9.3. Market Size and Forecast, By Animal Type
      • 8.2.9.4. Market Size and Forecast, By End User
  • 8.3. Europe
    • 8.3.1. Key Market Trends and Opportunities
    • 8.3.2. Market Size and Forecast, By Type
    • 8.3.3. Market Size and Forecast, By Vaccine
    • 8.3.4. Market Size and Forecast, By Animal Type
    • 8.3.5. Market Size and Forecast, By End User
    • 8.3.6. Market Size and Forecast, By Country
    • 8.3.7. Germany Brucellosis Vaccines Market
      • 8.3.7.1. Market Size and Forecast, By Type
      • 8.3.7.2. Market Size and Forecast, By Vaccine
      • 8.3.7.3. Market Size and Forecast, By Animal Type
      • 8.3.7.4. Market Size and Forecast, By End User
    • 8.3.8. France Brucellosis Vaccines Market
      • 8.3.8.1. Market Size and Forecast, By Type
      • 8.3.8.2. Market Size and Forecast, By Vaccine
      • 8.3.8.3. Market Size and Forecast, By Animal Type
      • 8.3.8.4. Market Size and Forecast, By End User
    • 8.3.9. UK Brucellosis Vaccines Market
      • 8.3.9.1. Market Size and Forecast, By Type
      • 8.3.9.2. Market Size and Forecast, By Vaccine
      • 8.3.9.3. Market Size and Forecast, By Animal Type
      • 8.3.9.4. Market Size and Forecast, By End User
    • 8.3.10. Italy Brucellosis Vaccines Market
      • 8.3.10.1. Market Size and Forecast, By Type
      • 8.3.10.2. Market Size and Forecast, By Vaccine
      • 8.3.10.3. Market Size and Forecast, By Animal Type
      • 8.3.10.4. Market Size and Forecast, By End User
    • 8.3.11. Spain Brucellosis Vaccines Market
      • 8.3.11.1. Market Size and Forecast, By Type
      • 8.3.11.2. Market Size and Forecast, By Vaccine
      • 8.3.11.3. Market Size and Forecast, By Animal Type
      • 8.3.11.4. Market Size and Forecast, By End User
    • 8.3.12. Rest of Europe Brucellosis Vaccines Market
      • 8.3.12.1. Market Size and Forecast, By Type
      • 8.3.12.2. Market Size and Forecast, By Vaccine
      • 8.3.12.3. Market Size and Forecast, By Animal Type
      • 8.3.12.4. Market Size and Forecast, By End User
  • 8.4. Asia-Pacific
    • 8.4.1. Key Market Trends and Opportunities
    • 8.4.2. Market Size and Forecast, By Type
    • 8.4.3. Market Size and Forecast, By Vaccine
    • 8.4.4. Market Size and Forecast, By Animal Type
    • 8.4.5. Market Size and Forecast, By End User
    • 8.4.6. Market Size and Forecast, By Country
    • 8.4.7. Japan Brucellosis Vaccines Market
      • 8.4.7.1. Market Size and Forecast, By Type
      • 8.4.7.2. Market Size and Forecast, By Vaccine
      • 8.4.7.3. Market Size and Forecast, By Animal Type
      • 8.4.7.4. Market Size and Forecast, By End User
    • 8.4.8. China Brucellosis Vaccines Market
      • 8.4.8.1. Market Size and Forecast, By Type
      • 8.4.8.2. Market Size and Forecast, By Vaccine
      • 8.4.8.3. Market Size and Forecast, By Animal Type
      • 8.4.8.4. Market Size and Forecast, By End User
    • 8.4.9. Australia Brucellosis Vaccines Market
      • 8.4.9.1. Market Size and Forecast, By Type
      • 8.4.9.2. Market Size and Forecast, By Vaccine
      • 8.4.9.3. Market Size and Forecast, By Animal Type
      • 8.4.9.4. Market Size and Forecast, By End User
    • 8.4.10. India Brucellosis Vaccines Market
      • 8.4.10.1. Market Size and Forecast, By Type
      • 8.4.10.2. Market Size and Forecast, By Vaccine
      • 8.4.10.3. Market Size and Forecast, By Animal Type
      • 8.4.10.4. Market Size and Forecast, By End User
    • 8.4.11. South Korea Brucellosis Vaccines Market
      • 8.4.11.1. Market Size and Forecast, By Type
      • 8.4.11.2. Market Size and Forecast, By Vaccine
      • 8.4.11.3. Market Size and Forecast, By Animal Type
      • 8.4.11.4. Market Size and Forecast, By End User
    • 8.4.12. Rest of Asia-Pacific Brucellosis Vaccines Market
      • 8.4.12.1. Market Size and Forecast, By Type
      • 8.4.12.2. Market Size and Forecast, By Vaccine
      • 8.4.12.3. Market Size and Forecast, By Animal Type
      • 8.4.12.4. Market Size and Forecast, By End User
  • 8.5. LAMEA
    • 8.5.1. Key Market Trends and Opportunities
    • 8.5.2. Market Size and Forecast, By Type
    • 8.5.3. Market Size and Forecast, By Vaccine
    • 8.5.4. Market Size and Forecast, By Animal Type
    • 8.5.5. Market Size and Forecast, By End User
    • 8.5.6. Market Size and Forecast, By Country
    • 8.5.7. Brazil Brucellosis Vaccines Market
      • 8.5.7.1. Market Size and Forecast, By Type
      • 8.5.7.2. Market Size and Forecast, By Vaccine
      • 8.5.7.3. Market Size and Forecast, By Animal Type
      • 8.5.7.4. Market Size and Forecast, By End User
    • 8.5.8. Saudi Arabia Brucellosis Vaccines Market
      • 8.5.8.1. Market Size and Forecast, By Type
      • 8.5.8.2. Market Size and Forecast, By Vaccine
      • 8.5.8.3. Market Size and Forecast, By Animal Type
      • 8.5.8.4. Market Size and Forecast, By End User
    • 8.5.9. South Africa Brucellosis Vaccines Market
      • 8.5.9.1. Market Size and Forecast, By Type
      • 8.5.9.2. Market Size and Forecast, By Vaccine
      • 8.5.9.3. Market Size and Forecast, By Animal Type
      • 8.5.9.4. Market Size and Forecast, By End User
    • 8.5.10. Rest of LAMEA Brucellosis Vaccines Market
      • 8.5.10.1. Market Size and Forecast, By Type
      • 8.5.10.2. Market Size and Forecast, By Vaccine
      • 8.5.10.3. Market Size and Forecast, By Animal Type
      • 8.5.10.4. Market Size and Forecast, By End User

CHAPTER 9: COMPETITIVE LANDSCAPE

  • 9.1. Introduction
  • 9.2. Top Winning Strategies
  • 9.3. Product Mapping of Top 10 Player
  • 9.4. Competitive Dashboard
  • 9.5. Competitive Heatmap
  • 9.6. Top Player Positioning, 2023

CHAPTER 10: COMPANY PROFILES

  • 10.1. Ceva Poultry
    • 10.1.1. Company Overview
    • 10.1.2. Key Executives
    • 10.1.3. Company Snapshot
    • 10.1.4. Operating Business Segments
    • 10.1.5. Product Portfolio
    • 10.1.6. Business Performance
    • 10.1.7. Key Strategic Moves and Developments
  • 10.2. Colorado Serum Company
    • 10.2.1. Company Overview
    • 10.2.2. Key Executives
    • 10.2.3. Company Snapshot
    • 10.2.4. Operating Business Segments
    • 10.2.5. Product Portfolio
    • 10.2.6. Business Performance
    • 10.2.7. Key Strategic Moves and Developments
  • 10.3. Creative Biolabs
    • 10.3.1. Company Overview
    • 10.3.2. Key Executives
    • 10.3.3. Company Snapshot
    • 10.3.4. Operating Business Segments
    • 10.3.5. Product Portfolio
    • 10.3.6. Business Performance
    • 10.3.7. Key Strategic Moves and Developments
  • 10.4. CZ Vaccines
    • 10.4.1. Company Overview
    • 10.4.2. Key Executives
    • 10.4.3. Company Snapshot
    • 10.4.4. Operating Business Segments
    • 10.4.5. Product Portfolio
    • 10.4.6. Business Performance
    • 10.4.7. Key Strategic Moves and Developments
  • 10.5. Fivet Animal Health
    • 10.5.1. Company Overview
    • 10.5.2. Key Executives
    • 10.5.3. Company Snapshot
    • 10.5.4. Operating Business Segments
    • 10.5.5. Product Portfolio
    • 10.5.6. Business Performance
    • 10.5.7. Key Strategic Moves and Developments
  • 10.6. Hester Biosciences Limited
    • 10.6.1. Company Overview
    • 10.6.2. Key Executives
    • 10.6.3. Company Snapshot
    • 10.6.4. Operating Business Segments
    • 10.6.5. Product Portfolio
    • 10.6.6. Business Performance
    • 10.6.7. Key Strategic Moves and Developments
  • 10.7. Indian Immunologicals Ltd
    • 10.7.1. Company Overview
    • 10.7.2. Key Executives
    • 10.7.3. Company Snapshot
    • 10.7.4. Operating Business Segments
    • 10.7.5. Product Portfolio
    • 10.7.6. Business Performance
    • 10.7.7. Key Strategic Moves and Developments
  • 10.8. Jordan Bio-industries Center
    • 10.8.1. Company Overview
    • 10.8.2. Key Executives
    • 10.8.3. Company Snapshot
    • 10.8.4. Operating Business Segments
    • 10.8.5. Product Portfolio
    • 10.8.6. Business Performance
    • 10.8.7. Key Strategic Moves and Developments
  • 10.9. Laboratories Tornel
    • 10.9.1. Company Overview
    • 10.9.2. Key Executives
    • 10.9.3. Company Snapshot
    • 10.9.4. Operating Business Segments
    • 10.9.5. Product Portfolio
    • 10.9.6. Business Performance
    • 10.9.7. Key Strategic Moves and Developments
  • 10.10. Merck And Co., Inc.
    • 10.10.1. Company Overview
    • 10.10.2. Key Executives
    • 10.10.3. Company Snapshot
    • 10.10.4. Operating Business Segments
    • 10.10.5. Product Portfolio
    • 10.10.6. Business Performance
    • 10.10.7. Key Strategic Moves and Developments